Lorestry’s Post

ICYMI: Watch our free #CME program with The American Macular Degeneration Foundation to understand the barriers preventing people with #nAMD or #DME from fully benefiting from anti-VEGF therapies ➡️ https://bit.ly/3VStRxP 🏷️ #MedEd #MedicalEducation #CME24

It's an exciting time for the team at Argenica Therapeutics, with the announcement that ARG-007 was recently granted orphan drug designation by the FDA. This status was given to ARG-007 for the potential treatment of hypoxic ischaemic encephalopathy (HIE), a condition that effects newborn babies. To give you some more insight into what this means for the company and why it's another major step in the right direction for ARG-007, Dr Liz Dallimore spoke with MarketOpen Australia recently. Watch the full overview below! #ASX #AGN #HIE #ARG007 #stroke #clinicaltrials

Read about one woman's experience participating in clinical trials for her MS, why she decided to do it, and what she's gained in the process. Go to: https://lnkd.in/e3KnkRBa #MyMSDiagnosis #WorldMSDay

WATCH: In this recent panel discussion for The Patient Story, Dr. M. Yair Levy of Texas Oncology speaks about how CLL patients can confidently empower themselves through shared treatment decision-making. #CLL #Leukemia #CommunityOncology

"𝘜𝘯𝘥𝘦𝘳𝘴𝘵𝘢𝘯𝘥𝘪𝘯𝘨 𝘵𝘩𝘦 𝘵𝘳𝘶𝘦 𝘪𝘮𝘱𝘢𝘤𝘵 𝘰𝘧 𝘺𝘰𝘶𝘳 𝘢𝘥𝘷𝘰𝘤𝘢𝘤𝘺 𝘦𝘧𝘧𝘰𝘳𝘵𝘴 𝘤𝘢𝘯 𝘧𝘦𝘦𝘭 𝘭𝘪𝘬𝘦 𝘯𝘢𝘷𝘪𝘨𝘢𝘵𝘪𝘯𝘨 𝘢 𝘮𝘢𝘻𝘦." Advocacy is crucial for improving patient care and reducing administrative burdens. Dr. Persing, from the University of South Alabama’s Mitchell Cancer Institute, emphasized the importance of engaging at the state level, where changes are more attainable. Here are two takeaways from his insights shared at the ASCO Annual Meeting ⬇ - 𝐏𝐞𝐫𝐬𝐨𝐧𝐚𝐥 𝐒𝐭𝐨𝐫𝐢𝐞𝐬 𝐌𝐚𝐭𝐭𝐞𝐫: Clinicians should leverage their expertise and personal stories to resonate with legislators. - 𝐄𝐧𝐠𝐚𝐠𝐞 𝐋𝐨𝐜𝐚𝐥𝐥𝐲: Meeting with lawmakers in their home states or districts can lead to more meaningful interactions. As Dr. Persing stated, "𝘋𝘰𝘯’𝘵 𝘣𝘦 𝘢𝘧𝘳𝘢𝘪𝘥 𝘵𝘰 𝘨𝘦𝘵 𝘪𝘯𝘷𝘰𝘭𝘷𝘦𝘥." Let’s continue to ensure patients are heard and our advocacy efforts are maximizing their impact. #PatientAdvocacy #PatientCare #ASCO #HealthcareProfessionals #HealthcareAdvocacy #HealthcareInnovation #PatientCenteredCare

Diversity in clinical trials - have you given any thoughts about your diversity plans? How exactly can you execute these plans? More importantly... where to even start? Fortrea offers a comprehensive and integrated "5-part process" solution for establishing, monitoring and reporting on Diversity Plan metrics in a clinical trials. Curious? Drop me a message! Or take a look at Joshua Richter's article - discusses the lack of diversity in clinical trials and how community oncologists can help overcome these disparities. #DiversityPlan #ClinicalTrials #oncology #diversity #Phase3

From adjusting #clinicaltrial design to ensuring the safety and well-being of children, this insightful paper delves into pediatric #drugdevelopment considerations and regulatory issues. Learn about adapting endpoints, obtaining informed consent for adolescents, and the vital role of parents, caregivers and patient advocacy groups in #patientrecruitment and retention. Explore the nuances of successful pediatric drug development. » https://bit.ly/3Tf0lAN

When it comes to successful #pediatric studies, children are not just small adults! PPD has more than 30 board certified pediatricians located across 6 continents to bring real life clinical expertise to our clients. Download our new Pediatric Clinical Trials White Paper for an introduction to how we use our collective experience to ensure the success of #drugdevelopment #clinicaltrials in infants, children and adolescents!

Did you know that the Canadian Agency for Drugs and Technologies in Health (CADTH) can now conditionally approve a therapy, rather than offering a definite yes or no? Here, Don Husereau (Adjunct Professor of Medicine, The University of Ottawa) explains that CADTH are taking this approach when they want to see more evidence for a therapy before signing off on reimbursement, but don't want to delay a treatment that could benefit patients. Offering conditional approval enables CADTH to ensure that innovative treatments are available to patients sooner than in the past, when they would have had to say no while, for example, awaiting further evidence from Phase 3 trials. So, what does this mean for your market access and HTA strategy? To discuss your evidence base and reimbursement options, arrange a call with our experts via [email protected] This clip was taken from our recent Global Whispers webinar where Don was a guest speaker. The webinar (first broadcast live in March 2024) is now available to watch on demand at: https://lnkd.in/ew8P4gDY #CADTH #HTA #healthtechnologyassessment #marketaccess #oncology #reimbursement #GlobalWhispers #Canada

The 340B drug pricing program has contributed to increasing consolidation in our #healthcare system. LUGPA supports reforms to 340B, including increased transparency and accountability. Learn more from our recent advocacy update: https://lnkd.in/eBtpc-3Z